| Drug Name |
Trabectedin |
| Drug ID |
BADD_D02253 |
| Description |
Trabectedin, also referred as ET-743 during its development, is a marine-derived antitumor agent discovered in the Carribean tunicate _Ecteinascidia turbinata_ and now produced synthetically. Trabectedin has a unique mechanism of action. It binds to the minor groove of DNA interfering with cell division and genetic transcription processes and DNA repair machinery. It is approved for use in Europe, Russia and South Korea for the treatment of advanced soft tissue sarcoma. It is currently under evaluation for the treatment of breast cancer, prostate cancer, in addition to pediatric sarcomas. Both the European Commission and the U.S. Food and Drug Administration (FDA) have approved trabectedin as an orphan drug in soft tissue sarcomas and ovarian cancer. On October 23, 2015, the FDA approved trabectedin, (as Yondelis), for the treatment of specific soft tissue sarcomas. |
| Indications and Usage |
Indicated for treatment of advanced soft tissue sarcoma in patients refractory to or unsuitable to receive anthracycline or ifosfamide chemotherapy in Europe, Russia and South Korea. Approved for orphan drug status by the U.S. FDA for treatment of soft tissue sarcomas and ovarian cancer. Investigated for use/treatment in cancer/tumors (unspecified), gastric cancer, ovarian cancer, pediatric indications, sarcoma, and solid tumors. |
| Marketing Status |
approved; investigational |
| ATC Code |
L01CX01 |
| DrugBank ID |
DB05109
|
| KEGG ID |
D06199
|
| MeSH ID |
D000077606
|
| PubChem ID |
108150
|
| TTD Drug ID |
D03RTK
|
| NDC Product Code |
59676-610; 42973-310; 54893-0092; 70225-1110; 57884-0033 |
| UNII |
ID0YZQ2TCP
|
| Synonyms |
Trabectedin | Yondelis | Ecteinascidin 743 | ET-743 | ET743 | ET 743 | NSC 684766 |
